Here we report that HB1.F3 NSCs can be engineered to express and secrete functional full-length HER2-specific human immunoglobulin molecules that can selectively bind to and inhibit the proliferation of HER2-positive breast carcinoma cells. Here, ERBB2 is linked to breast carcinoma.